MOBERG PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.58 SEK | -6.02% |
|
-9.20% | +101.18% |
| Sales 2022 | 207K 18.9K | Sales 2023 | - | Capitalization | 425M 38.8M |
|---|---|---|---|---|---|
| Net income 2022 | -15M -1.37M | Net income 2023 | -21M -1.92M | EV / Sales 2022 | 524 x |
| Net cash position 2022 | 119M 10.91M | Net cash position 2023 | 55.82M 5.1M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-11
x | P/E ratio 2023 |
-11.4
x | Employees | 10 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 68.12% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -6.48% | ||
| 1 week | -9.20% | ||
| Current month | +35.31% | ||
| 1 month | +74.74% | ||
| 3 months | +97.29% | ||
| 6 months | +377.81% | ||
| Current year | +101.18% |
1 week
29.06
38.14
1 month
15.6040.90
Current year
13.3040.90
1 year
6.1540.90
3 years
6.1575.50
5 years
6.15806.00
10 years
6.15861.00
| Managers | Title | Age | Since |
|---|---|---|---|
Anna Ljung
CEO | Chief Executive Officer | 44 | 05-12-31 |
Mark Beveridge
DFI | Director of Finance/CFO | 46 | 19-10-17 |
| Chief Tech/Sci/R&D Officer | 60 | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anders Lundmark
BRD | Director/Board Member | 66 | 22-05-15 |
Håkan Wallin
BRD | Director/Board Member | 62 | - |
Nikolaj Sørensen
BRD | Director/Board Member | 52 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 30.58 | -6.02% | 989 045 |
| 24-04-15 | 32.54 | -10.80% | 630,901 |
| 24-04-12 | 36.48 | +1.50% | 577,995 |
| 24-04-11 | 35.94 | +11.61% | 515,500 |
| 24-04-10 | 32.2 | -4.39% | 512,457 |
Delayed Quote Nasdaq Stockholm, April 16, 2024 at 11:29 am EDT
More quotes
Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +101.18% | 83.65M | |
| +28.60% | 676B | |
| +24.27% | 559B | |
| -7.38% | 356B | |
| +15.36% | 320B | |
| +5.41% | 286B | |
| +2.62% | 213B | |
| +0.15% | 207B | |
| -9.41% | 199B | |
| -7.96% | 142B |
- Stock Market
- Equities
- MOB Stock
